Cargando…

Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

PURPOSE: To investigate the therapeutic effectiveness and safety of Janus kinase 1 inhibitor upadacitinib in adolescent patients with atopic dermatitis (AD). PATIENTS AND METHODS: This study examined therapeutic effectiveness and safety of upadacitinib for 39 Japanese adolescent patients (aged 12–17...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hagino, Teppei, Hamada, Risa, Yoshida, Mai, Fujimoto, Eita, Saeki, Hidehisa, Kanda, Naoko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638939/ https://www.ncbi.nlm.nih.gov/pubmed/37953857 http://dx.doi.org/10.2147/CCID.S439053

Ejemplares similares

The Eosinophil-to-Lymphocyte Ratio Acts as an Indicator for Improvement of Clinical Signs and Itch by Upadacitinib Treatment in Atopic Dermatitis
por: Hagino, Teppei, et al.
Publicado: (2023)

Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis
por: Hagino, Teppei, et al.
Publicado: (2023)

The Roles of Sex Hormones in the Course of Atopic Dermatitis
por: Kanda, Naoko, et al.
Publicado: (2019)

A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis
por: Katoh, Norito, et al.
Publicado: (2021)

Biomarkers and Predictive Factors for Treatment Response to Tumor Necrosis Factor-α Inhibitors in Patients with Psoriasis
por: Hagino, Teppei, et al.
Publicado: (2023)

A Case of Darier’s Disease with a Novel Missense Mutation in ATP2A2 Successfully Treated with Calcipotriol/Betamethasone Dipropionate Two-Compound Ointment
por: Hagino, Teppei, et al.
Publicado: (2022)

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib
por: Grieco, Teresa, et al.
Publicado: (2023)

Dietary Fiber Inulin Improves Murine Imiquimod-Induced Psoriasis-like Dermatitis
por: Yoshida, Mai, et al.
Publicado: (2023)

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study
por: Katoh, Norito, et al.
Publicado: (2022)

Exacerbation of human papillomavirus infection with initiation of upadacitinib for atopic dermatitis
por: Seale, Emily, et al.
Publicado: (2023)

Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults
por: De Greef, Axel, et al.
Publicado: (2023)

Growth analysis among adolescents with moderate-to-severe atopic dermatitis receiving upadacitinib in combination with topical corticosteroids in Japan: A case study series from a phase 3, randomized, controlled trial (Rising Up)
por: Tanaka, Toshiaki, et al.
Publicado: (2022)

Addressing topical corticosteroid phobia in atopic dermatitis: The role of the pharmacist
por: Ladda, Matthew, et al.
Publicado: (2021)

Proactive versus Rank-Down Topical Corticosteroid Therapy for Maintenance of Remission in Pediatric Atopic Dermatitis: A Randomized, Open-Label, Active-Controlled, Parallel-Group Study (Anticipate Study)
por: Kamiya, Koji, et al.
Publicado: (2022)

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis
por: Wan, Huiying, et al.
Publicado: (2022)

Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS‐J): Baseline characteristics, treatment history and disease burden
por: Katoh, Norito, et al.
Publicado: (2019)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

Atopic dermatitis treated with tralokinumab and upadacitinib combination therapy: A case report
por: Lansang, Rafael Paolo, et al.
Publicado: (2023)

Cortisol Homeostasis in the Epidermis is Influenced by Topical Corticosteroids in Patients with Atopic Dermatitis
por: Fukaya, Mototsugu
Publicado: (2017)

Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study
por: Chiricozzi, Andrea, et al.
Publicado: (2022)

Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report
por: Cantelli, Mariateresa, et al.
Publicado: (2022)

Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
por: Gao, Qin, et al.
Publicado: (2023)

The long‐term safety of topical corticosteroids in atopic dermatitis: A systematic review
por: Harvey, Jane, et al.
Publicado: (2023)

Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis
por: Nakagawa, Hidemi, et al.
Publicado: (2019)

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Reich, Kristian, et al.
Publicado: (2020)

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere)
por: Simpson, Eric L., et al.
Publicado: (2023)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
por: Nezamololama, Novin, et al.
Publicado: (2020)

Acne keloidalis nuchae in a patient with atopic dermatitis treated with Janus kinase inhibitor upadacitinib
por: Caudrelier, Nicolas, et al.
Publicado: (2023)

Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis
por: Silverberg, Jonathan I., et al.
Publicado: (2023)

Dupilumab in the management of topical corticosteroid withdrawal in atopic dermatitis: A retrospective case series
por: Arnold, Kathryn A., et al.
Publicado: (2018)

Topical corticosteroid phobia in parents of pediatric patients with atopic dermatitis: a multicentre survey
por: El Hachem, Maya, et al.
Publicado: (2017)

Nano intervention in topical delivery of corticosteroid for psoriasis and atopic dermatitis—a systematic review
por: Shetty, Kshitya, et al.
Publicado: (2021)

Topical corticosteroids normalize both skin and systemic inflammatory markers in infant atopic dermatitis
por: McAleer, M. A., et al.
Publicado: (2021)

Phase 2, randomized, double‐blind, placebo‐controlled, 4‐week study to evaluate the safety and efficacy of OPA‐ 15406 (difamilast), a new topical selective phosphodiesterase type‐4 inhibitor, in Japanese pediatric patients aged 2–14 years with atopic dermatitis
por: Saeki, Hidehisa, et al.
Publicado: (2019)

Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis
por: Silverberg, Jonathan I., et al.
Publicado: (2022)

Bridging to a selective Janus kinase 1 inhibitor in severe atopic dermatitis: An instructive case with upadacitinib
por: Nguyen, Jannett, et al.
Publicado: (2020)

Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: A case report
por: Bourkas, Adrienn N, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dr2s2l0u2p6j2c3vmiujjfbuul